Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
2 hedge funds and large institutions have $166K invested in Juno Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 232 closing their positions.
99% less funds holding
Funds holding: 237 → 2 (-235)
100% less funds holding in top 10
Funds holding in top 10: 9 → 0 (-9)
100% less capital invested
Capital invested by funds: $3.7B → $166K (-$3.7B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 232
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$482M |
| 2 |
CM
Crestline Management
Fort Worth,
Texas
|
-$349M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$320M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$287M |
| 5 |
BlackRock
New York
|
-$221M |
JUNO Hedge Fund Activity: Q1 2018 in Review
2 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q1 2018, worth a combined $166K — down 100% from $3.7B a quarter earlier.
Sellers outnumbered buyers: 232 funds closed out of JUNO and 0 opened new positions — a net loss of 232 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $482M sold.
- 2 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q1 2018, down from 237 in Q4 2017.
- Funds reported $166K of Juno Therapeutics, Inc. stock for Q1 2018, down 100% quarter-over-quarter.
- 0 funds opened new Juno Therapeutics, Inc. positions in Q1 2018 and 232 closed out, a net change of -232 holders.
- The largest Juno Therapeutics, Inc. seller in Q1 2018 was Baillie Gifford & Co, an estimated $482M sold.
Based on aggregated 13F filings for Q1 2018.